retatrutide latest clinical trial results VisualAbstract: reduces body weight by 17.5% in patients with obesity Medscape | Retatrutide, Eli Lilly's

This stands in stark contrast to the average weight loss seen with GLP-1 medications , which often ranges from 10 to 20 percent of body weight depending on the specific drug and dose

Dual peptides for the treatment of obesity Tirzepatide, a novel dual GIP and GLP-1RA, offers significant insights into its mechanism of action, therapeutic benefits, and clinical applications for the management of T2D and obesity in general practice

Food as Medicine vs

Lifestyle modifications established during research provide maintenance foundation

Helps convert food into cellular energy These statements have not been evaluated by the Food and Drug Administration